Peña Bruno, Barhoumi Rola, Burghardt Robert C, Turro Claudia, Dunbar Kim R
Department of Chemistry, Texas A&M University , College Station, Texas 77842, United States.
J Am Chem Soc. 2014 Jun 4;136(22):7861-4. doi: 10.1021/ja503774m. Epub 2014 May 22.
The new dirhodium compound [Rh2(μ-O2CCH3)2(η(1)-O2CCH3)(phenbodipy)(H2O)3][O2CCH3] (1), which incorporates a bodipy fluorescent tag, was prepared and studied by confocal fluorescence microscopy in human lung adenocarcinoma (A549) cells. It was determined that 1 localizes mainly in lysosomes and mitochondria with no apparent nuclear localization in the 1-100 μM range. These results support the conclusion that cellular organelles rather than the nucleus can be targeted by modification of the ligands bound to the Rh2(4+) core. This is the first study of a fluorophore-labeled metal-metal bonded compound, work that opens up new venues for the study of intracellular distribution of dinuclear transition metal anticancer complexes.
合成了一种新的二铑化合物[Rh2(μ-O2CCH3)2(η(1)-O2CCH3)(phenbodipy)(H2O)3][O2CCH3](1),该化合物含有一个硼二吡咯荧光标签,并通过共聚焦荧光显微镜在人肺腺癌(A549)细胞中进行了研究。结果表明,在1-100μM范围内,化合物1主要定位于溶酶体和线粒体,无明显的核定位。这些结果支持这样的结论:通过修饰与Rh2(4+)核心结合的配体,可以靶向细胞器而非细胞核。这是对荧光团标记的金属-金属键合化合物的首次研究,这项工作为研究双核过渡金属抗癌配合物的细胞内分布开辟了新途径。